Zhang Xinmin, an official at China’s science and technology ministry, said favipiravir, developed by a subsidiary of Fujifilm, had produced encouraging outcomes in clinical trials in Wuhan and Shenzhen involving 340 patients.
“It has a high degree of safety and is clearly effective in treatment,” Zhang told reporters on Tuesday.
Active Motif just announced the launch of 9 different recombinant human COVID-19 antibodies that are specific for the SARS-CoV-2 Spike protein S1. Read more here: https://www.activemotif.com/blog-covid19-abs